Home - אומניקס מדיקל - Omnix Medical

Bringing The Next-Generation Of Antibiotics

to win the war against resistant bacteria

Our Vision

Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. We are offering an exceptional technology with a first-in-its-class drug that will be a gamechanger in the anti-infective industry.

Our company

Omnix Medical is a biopharmaceutical company

Founded in 2015, Omnix Medical is developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria.

Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.

Our technology

Our exceptional technology offers a first-in-its-class drug

Omnix has overcome the two main barriers that stand in the way of using antimicrobial peptides as effective therapeutic agents – stability and selectivity. We are able to produce selective, degradation-resistant peptides that are highly potent by both synthesis and biochemical engineering approaches.

Our partners

Moving together towards a better future

Our partners

MOVING TOGETHER TOWARDS A BETTER FUTURE

WE AT OMNIX MEDICAL

ARE ALWAYS LOOKING FOR EXTRAORDINARY PEOPLE TO JOIN OUR TEAM

Company News

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S.

OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office

We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment

Contact Us

Reach US

A-2-Z - Digital Accessibility and Marketing

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).